Significant PFS Improvement at 3 Years with Neoadjuvant dd-MVAC Regimen in Patients with MIBC
Results of the GETUG/AFU VESPER V05 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1616 results
Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer
The results from a prospective, phase III clinical study of extended treatment with 5 years of letrozole compared to 2 to 3 years of letrozole
Bintrafusp Alfa Shows the Long-Term Efficacy and Safety in Patients with HPV–Associated Malignancies
The results from the studies conducted in patients with human papillomavirus associated malignancies
Intermittent Relacorilant Combined with Nab-paclitaxel Improves PFS in Recurrent Platinum-Resistant Ovarian Cancer
Findings from a randomised, open-label, phase II study
FDA Grants Accelerated Approval to Mobocertinib for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
FDA also approved the Oncomine Dx Target Test as a companion diagnostic device
Epcoritamab Shows a Manageable Safety and Robust Antitumour Activity in Heavily Pretreated B-Cell Non-Hodgkin Lymphoma
Findings from a first-in-human phase I/II study that evaluated subcutaneous, highly selective and potent bispecific antibody targeting CD3 and CD20
Long-Term, Poorly Controlled Diabetes May Impair Efficacy of Immune Checkpoint Inhibitors
Findings from a large, multicentre, retrospective cohort of patients with advanced cancer
New Safety Signal for Use of Ibrutinib in Combination with Rituximab and ACE Inhibitors
An increased risk of sudden or cardiac death
Single-Fraction SABR Preferred from Resource and Patient Perspectives for Pulmonary Oligometastases
The results from the SAFRON II study of single-fraction versus multifraction stereotactic ablative body radiotherapy
Lack of Evidence for the Use of Telemedicine in the Prevention and Surveillance for Recurrences and New Cancers
MASCC Survivorship Study Group points to evidence availability for telemedicine interventions only in addressing the psychosocial and physical effects of cancer
Pivotal Role of the Institutional Molecular Tumour Board in Evaluating the Results of a Customised Next-Generation Sequencing Panel
The results of the MAST study
No Benefit of Additional Tumour Testing in HER2-negative Metastatic Breast Cancer with Already Confirmed Germline BRCA Mutations
Findings from a prespecified exploratory analysis of the OlympiAD study